KPNA6: A Potential Drug Target and Biomarker (G23633)

Target Name: KPNA6

NCBI ID: G23633

KPNA6

KPNA6: A Potential Drug Target and Biomarker

Krilloplastide A6 (KPNA6) is a protein that is expressed in the nuclei of all eukaryotic cells. It is a member of the Importin subunit alpha-7 family, which is responsible for importing foreign DNA into the cell. KPNA6 plays a crucial role in this process, as it is the protein that interacts with the foreign DNA and helps to facilitate its entry into the cell.

Recent studies have identified KPNA6 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The discovery of KPNA6 as a drug target is significant because it has the potential to treat a wide range of diseases that are currently untreatable or have limited treatment options.

One of the key reasons why KPNA6 is considered a potential drug target is its involvement in the development and progression of cancer. Many studies have shown that KPNA6 is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, experiments have shown that inhibiting KPNA6 can lead to the regression of cancerous tumors in cell culture models. These findings suggest that KPNA6 may be a valuable target for cancer treatment.

Another potential drug target for KPNA6 is its role in neurodegenerative diseases. Many of these diseases, such as Alzheimer's and Parkinson's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. KPNA6 has been shown to be involved in the development and progression of these diseases, and inhibiting its activity has been shown to protect against neurodegeneration in animal models.

In addition to its potential role in cancer and neurodegenerative diseases, KPNA6 has also been identified as a potential biomarker for these conditions. The loss of KPNA6 has been observed in the brains of individuals with Alzheimer's disease, and these losses were associated with the development of neurofibrillary tangles and the progressive loss of brain cells. Similarly, KPNA6 has been shown to be involved in the development and progression of Parkinson's disease, and its loss has been associated with the development of neurofibrillary tangles and the progressive loss of brain cells. These findings suggest that KPNA6 may be a valuable biomarker for the diagnosis and progression of neurodegenerative diseases.

In conclusion, the discovery of KPNA6 as a potential drug target and biomarker is significant because it has the potential to treat a wide range of diseases that are currently untreatable or have limited treatment options. The regulation of KPNA6 is a complex process that is still being fully understood, and further research is needed to fully explore its role in disease progression and treatment.

Protein Name: Karyopherin Subunit Alpha 6

Functions: Functions in nuclear protein import as an adapter protein for nuclear receptor KPNB1. Binds specifically and directly to substrates containing either a simple or bipartite NLS motif. Docking of the importin/substrate complex to the nuclear pore complex (NPC) is mediated by KPNB1 through binding to nucleoporin FxFG repeats and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to importin-beta and the three components separate and importin-alpha and -beta are re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran from importin. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus

The "KPNA6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KPNA6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets